WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder

Dan J. Stein, Borwin Bandelow, Eric Hollander, David J. Nutt, Ahmed Okasha, Mark H. Pollack, Richard P. Swinson, Joseph Zohar

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Posttraumatic stress disorder (PTSD) is a common and disabling condition. In addition to combat-related PTSD, the disorder occurs in civilians exposed to severe traumatic events, with the community prevalence rate for the combined populations reaching as high as 12%. If left untreated, PTSD may continue for years after the stressor event, resulting in severe functional and emotional impairment and a dramatic reduction in quality of life, with negative economic consequences for both the sufferer and society as a whole. Although PTSD is often overlooked, diagnosis is relatively straight-forward once a triggering stressor event and the triad of persistent symptoms-reexperiencing the traumatic event, avoiding stimuli associated with the trauma, and hyperarousal-have been identified. However, comorbid conditions of anxiety and depression frequently hamper accurate diagnosis. Treatment for PTSD includes psychotherapy and pharmacotherapy. The latter includes selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors. Only SSRIs have been proven effective and safe in long-term randomized controlled trials. Current guidelines from the Expert Consensus Panel for PTSD recommend treatment of chronic PTSD for a minimum of 12-24 months.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalCNS Spectrums
Volume8
Issue number8 SUPPL. 1
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Post-Traumatic Stress Disorders
Serotonin Uptake Inhibitors
Therapeutics
Monoamine Oxidase Inhibitors
Tricyclic Antidepressive Agents
Psychotherapy
Consensus
Anxiety
Randomized Controlled Trials
Economics
Quality of Life
Guidelines
Depression
Drug Therapy
Wounds and Injuries
Population

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Stein, D. J., Bandelow, B., Hollander, E., Nutt, D. J., Okasha, A., Pollack, M. H., ... Zohar, J. (2003). WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. CNS Spectrums, 8(8 SUPPL. 1), 31-39.

WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. / Stein, Dan J.; Bandelow, Borwin; Hollander, Eric; Nutt, David J.; Okasha, Ahmed; Pollack, Mark H.; Swinson, Richard P.; Zohar, Joseph.

In: CNS Spectrums, Vol. 8, No. 8 SUPPL. 1, 08.2003, p. 31-39.

Research output: Contribution to journalArticle

Stein, DJ, Bandelow, B, Hollander, E, Nutt, DJ, Okasha, A, Pollack, MH, Swinson, RP & Zohar, J 2003, 'WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder', CNS Spectrums, vol. 8, no. 8 SUPPL. 1, pp. 31-39.
Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH et al. WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. CNS Spectrums. 2003 Aug;8(8 SUPPL. 1):31-39.
Stein, Dan J. ; Bandelow, Borwin ; Hollander, Eric ; Nutt, David J. ; Okasha, Ahmed ; Pollack, Mark H. ; Swinson, Richard P. ; Zohar, Joseph. / WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder. In: CNS Spectrums. 2003 ; Vol. 8, No. 8 SUPPL. 1. pp. 31-39.
@article{dafd7a68faae416cb782c2afe7ec9991,
title = "WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder",
abstract = "Posttraumatic stress disorder (PTSD) is a common and disabling condition. In addition to combat-related PTSD, the disorder occurs in civilians exposed to severe traumatic events, with the community prevalence rate for the combined populations reaching as high as 12{\%}. If left untreated, PTSD may continue for years after the stressor event, resulting in severe functional and emotional impairment and a dramatic reduction in quality of life, with negative economic consequences for both the sufferer and society as a whole. Although PTSD is often overlooked, diagnosis is relatively straight-forward once a triggering stressor event and the triad of persistent symptoms-reexperiencing the traumatic event, avoiding stimuli associated with the trauma, and hyperarousal-have been identified. However, comorbid conditions of anxiety and depression frequently hamper accurate diagnosis. Treatment for PTSD includes psychotherapy and pharmacotherapy. The latter includes selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors. Only SSRIs have been proven effective and safe in long-term randomized controlled trials. Current guidelines from the Expert Consensus Panel for PTSD recommend treatment of chronic PTSD for a minimum of 12-24 months.",
author = "Stein, {Dan J.} and Borwin Bandelow and Eric Hollander and Nutt, {David J.} and Ahmed Okasha and Pollack, {Mark H.} and Swinson, {Richard P.} and Joseph Zohar",
year = "2003",
month = "8",
language = "English (US)",
volume = "8",
pages = "31--39",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "8 SUPPL. 1",

}

TY - JOUR

T1 - WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder

AU - Stein, Dan J.

AU - Bandelow, Borwin

AU - Hollander, Eric

AU - Nutt, David J.

AU - Okasha, Ahmed

AU - Pollack, Mark H.

AU - Swinson, Richard P.

AU - Zohar, Joseph

PY - 2003/8

Y1 - 2003/8

N2 - Posttraumatic stress disorder (PTSD) is a common and disabling condition. In addition to combat-related PTSD, the disorder occurs in civilians exposed to severe traumatic events, with the community prevalence rate for the combined populations reaching as high as 12%. If left untreated, PTSD may continue for years after the stressor event, resulting in severe functional and emotional impairment and a dramatic reduction in quality of life, with negative economic consequences for both the sufferer and society as a whole. Although PTSD is often overlooked, diagnosis is relatively straight-forward once a triggering stressor event and the triad of persistent symptoms-reexperiencing the traumatic event, avoiding stimuli associated with the trauma, and hyperarousal-have been identified. However, comorbid conditions of anxiety and depression frequently hamper accurate diagnosis. Treatment for PTSD includes psychotherapy and pharmacotherapy. The latter includes selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors. Only SSRIs have been proven effective and safe in long-term randomized controlled trials. Current guidelines from the Expert Consensus Panel for PTSD recommend treatment of chronic PTSD for a minimum of 12-24 months.

AB - Posttraumatic stress disorder (PTSD) is a common and disabling condition. In addition to combat-related PTSD, the disorder occurs in civilians exposed to severe traumatic events, with the community prevalence rate for the combined populations reaching as high as 12%. If left untreated, PTSD may continue for years after the stressor event, resulting in severe functional and emotional impairment and a dramatic reduction in quality of life, with negative economic consequences for both the sufferer and society as a whole. Although PTSD is often overlooked, diagnosis is relatively straight-forward once a triggering stressor event and the triad of persistent symptoms-reexperiencing the traumatic event, avoiding stimuli associated with the trauma, and hyperarousal-have been identified. However, comorbid conditions of anxiety and depression frequently hamper accurate diagnosis. Treatment for PTSD includes psychotherapy and pharmacotherapy. The latter includes selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors. Only SSRIs have been proven effective and safe in long-term randomized controlled trials. Current guidelines from the Expert Consensus Panel for PTSD recommend treatment of chronic PTSD for a minimum of 12-24 months.

UR - http://www.scopus.com/inward/record.url?scp=1542379604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542379604&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 31

EP - 39

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 8 SUPPL. 1

ER -